

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07K 7/56	A1	(11) International Publication Number: WO 97/47645 (43) International Publication Date: 18 December 1997 (18.12.97)
(21) International Application Number: PCT/US97/09833 (22) International Filing Date: 10 June 1997 (10.06.97)	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 60/020,483 14 June 1996 (14.06.96) US 9614325.0 8 July 1996 (08.07.96) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEONARD, William (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BELYK, Kevin, M. (US/US); 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: A PROCESS FOR PREPARING CERTAIN AZA CYCLOHEXAPEPTIDES		
(57) Abstract <p>There is disclosed a novel process for preparing aza cyclohexapeptides of formula (I) where all variables are defined herein.</p> <div data-bbox="779 1197 1380 1848"><p style="text-align: right;">(I)</p></div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						


TITLE OF THE INVENTION**A PROCESS FOR PREPARING CERTAIN AZA CYCLO-
HEXAPEPTIDES****BACKGROUND OF THE INVENTION**

This invention relates to an improved process for preparing certain aza cyclohexapeptides of the kind disclosed in U.S. Patent No. 5,378,804 which issued January 3, 1995. The initial process disclosed to synthesize these compounds required five steps and was not significantly stereoselective or high yielding. Known reductions of primary amides, such as hydrogenation, metal hydride and electrochemical reduction, require forcing conditions incompatible with the other amides and functional groups in the pneumocandin series. These reductions suffer from lack of chemoselectivity among differently substituted amides. An improved three step process was disclosed in copending application serial no. 08/386,618, however, this process has a maximum chemical yield in the range of about 23-25%. The new process described herein results in higher yields and easier synthesis of analogs of the compounds.

SUMMARY OF THE INVENTION

This invention is directed to a process for preparing aza cyclohexapeptides of the formula:

- 2 -



wherein

R_1 is $\text{CH}_2\text{CH}_2\text{NH}_2$ or CH_2CONH_2 ;

R^I is C₉-C₂₁ alkyl,
C₉-C₂₁ alkenyl,
C₁-C₁₀ alkoxyphenyl,
C₁-C₁₀ alkoxyphenyl; or
C₁-C₁₀ alkoxyphenyl;

R^{II} is H, C₁-C₄ alkyl,
C₃-C₄ alkenyl,
(CH₂)₂₋₄OH, or
(CH₂)₂₋₄NR^{IV}R^V;

R^{III} is H, C₁-C₄ alkyl C₃-C₄ alkenyl, (CH₂)₂₋₄OH,
(CH₂)₂₋₄NR^{IV}R^V, or

- 3 -

R^{II} and
R^{III} taken together are (CH₂)₄, (CH₂)₅, (CH₂)₂O(CH₂)₂ or
(CH₂)₂NH(CH₂)₂;

R^{IV} is H or C₁-C₄ alkyl;

R^V is H or C₁-C₄ alkyl;

Q is N or O; or

pharmaceutically acceptable acid addition salts thereof.

The compounds prepared by the process of this invention have been found to be useful in treating fungal infections especially those caused by *Candida*, *Aspergillus*, *Histoplasma*, *Coccidioides* and *Blastomyces*. They have also been found useful for the treatment and prevention of infections caused by *Pneumocystis carinii* which are often found in immunocompromised patients such as those with AIDS.

There are also disclosed novel intermediates useful in the process of the invention.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a process for preparing compounds of formula (I) through a stereoselective, high yielding process.

Throughout the specification and appended claims, a given chemical formula or name shall encompass all optical and stereoisomers as well as racemic mixtures where such isomers and mixtures exist.

The term alkyl refers to straight, branched or cyclic chain hydrocarbon groups, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, pentyl, hexyl, heptyl, cyclopentyl, cyclohexyl, cyclohexylmethyl and the like.

The term cycloalkyl refers to a species of alkyl containing from 3 to 15 carbon atoms without alternating or resonating double bonds between carbon atoms.

The term alkenyl refers to groups such as, e.g., vinyl, 1-propene-2-yl, 1-butene-4-yl, 2-buten-4-yl, 1-pentene-5-yl and the like.

The term alkoxy refers to straight or branched chain oxyalkyl groups such as, e.g., methoxy, ethoxy, butoxy, heptoxy, dodecyloxy, and the like.


The compounds of the present invention are generally obtained as mixtures of stereoisomeric forms in which one form usually predominates. Conditions may be adjusted by means within the normal skill of the skilled artisan to obtain predominantly the desired isomer. The compounds with preferred stereoisomeric form designated herein as the "normal" form are those in which the group at the "C-5-orn" position is below the plane at the said position. The designation "epi" has been employed for those compounds in which the group at the "C-5-orn" position is above the plane. The "C-5-orn" position is defined as the 5-carbon on the 4-hydroxy ornithine component.

The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts. Examples of acid salts are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or prodrug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and


tetramethylammonium hydroxide. These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base, or alternatively by reacting a free base with a suitable organic or inorganic acid.

Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

In a preferred embodiment, the process of this invention comprises the steps of reacting Compound II of the formula:




with phenylboronic acid to afford Compound III of the formula:




which is subsequently reduced to the amine and then hydrolyzed to afford Compound IV of the formula:

- 7 -




which is stereoselectively converted to Compound I through Compound V of the formula:




by displacement of the phenylthio group.

In an alternative embodiment, the process comprises the steps of reacting Compound II of the formula:


- 9 -




with thiophenol to afford Compound VI of the formula:



subsequently reacting Compound VI with phenylboronic acid to afford Compound IIIa of the formula:




which is subsequently reduced to the amine and then hydrolyzed to afford Compound V of the formula:



which is stereoselectively converted to Compound I by displacement of the phenylthio group.


Compound II where R¹ is dimethyltridecyl, is disclosed and claimed in U.S. Patent No. 5,202,309, which is incorporated herein by reference. Compound II can be produced by cultivating *Zalerion arboricola* ATCC 20868 in a nutrient medium enriched in mannitol as the primary source of carbon as described in US Patent No. 5,021,341, which is also incorporated herein by reference.

A preferred compound prepared by the process of the invention is shown below:






A second preferred compound prepared by the process of the invention is shown below:


- 13 -



The invention is illustrated in the following steps wherein preferred reactants are shown to more clearly demonstrate the process of the invention. R^{I} is dimethyltridecyl in the following reaction schemes.

REACTION SCHEME I





SCHEME I

As shown above, Step 1 involves the formation of the bis(phenylboronate) compound (Compound III) by reacting Compound II and dry THF with phenylboronic acid, p-methoxyphenylboronic acid or methanaboronic acid. 1-10 mole equivalents of the acid can be employed with 1-3 mole equivalents preferred.

Step 2 involves the reduction of Compound III to the amine (Compound IV) using a borane complex such as borane with tetrahydrofuran (THF), dimethylsulfide, diphenylsulfide, dibenzylsulfide, 1,4-oxathiane or BH_2Cl with dimethylsulfide or a metal boride such as $\text{ZrCl}_4/\text{NaBH}_4$ or $\text{TiCl}_4/\text{NaBH}_4$ in THF or other suitable solvent. The reduction may also be carried out using borane complexes with ammonia, dimethylamine, pyridine or piperazine. Preferred reduction agents include the borane complexes with tetrahydrofuran

(THF), dimethylsulfide, diphenylsulfide, dibenzylsulfide, 1,4-oxathiane or BH_2Cl with dimethylsulfide or a metal boride such as $\text{ZrCl}_4/\text{NaBH}_4$ or $\text{TiCl}_4/\text{NaBH}_4$ in THF or other suitable solvent. Any amide unconverted by this reduction is separated using reverse phase chromatography. Following the reduction, Step 2 also involves the removal of the phenylboronate groups during workup with aqueous acid.

Step 3 involves two parts. First of all, the reaction of Compound IV with thiophenol in acetonitrile and trifluoroacetic acid (TFA) to produce a phenylsulfide containing intermediate. Any moderate strength acid is expected to produce the intermediate in good yield. Examples of such moderate strength acids include, but are not limited to, trifluoroacetic acid, phosphoric acid and trichloroacetic acid. Other sulfides such as 4-methoxythiophenol, 2-mercapto-1-methylimidazole and 2-mercaptobenzimidazole may be employed. Compound III is extracted by application of the diluted reaction solution to a reverse phase C-18 column, followed by elution with methanol.

The amount of TFA used is crucial to the rate of displacement as well as to the subsequent formation of the undesired sulfide at the homotyrosine segment of the cyclic peptide. It was found that from about 5% to about 25% TFA in acetonitrile gave the best yield and process aging time. The preferred TFA range was found to be from about 7% to about 15%.

The amount of thiophenol used in this step is also critical to the yield of the final product. 3 to 5 equivalents of the thiophenol provided the best yield.


The preferred conditions for the sulfide formation were determined to be 5 equivalents thiophenol in 10% TFA/acetonitrile at 0°C . These conditions resulted in a yield of 65-70% after solid phase extraction.

The second part of Step 3 involves the displacement of the phenylthio group. The phenylsulfide is reacted in neat ethylenediamine (1:3) at ambient temperature to provide Compound Ia in 95% yield. The reaction may take place at a temperature of about 10°C to about



- 18 -


40°C for about 0.5 to about 6.0 hours. Preferably the reaction takes place at room temperature for about 1.5 hours. The reaction can also be conducted using ethylenediamine dissolved in a suitable solvent such as water, methanol, ethanol, isopropanol, tetrahydrofuran, trifluoroethanol, dichloroethane or acetonitrile.


REACTION SCHEME II



- 19 -







SCHEME II

As shown above, Step 1 involves the reaction of Compound II with thiophenol in acetonitrile and trifluoroacetic acid (TFA) to produce a phenylsulfide containing intermediate. Any moderate strength acid is expected to produce the intermediate in good yield. Examples of such moderate strength acids include, but are not limited to, trifluoroacetic acid, phosphoric acid and trichloroacetic acid. Other sulfides such as 4-methoxythiophenol, 2-mercapto-1-methylimidazole and 2-mercaptobenzimidazole may be employed. Compound VI is precipitated by addition of water and isolated by filtration.

The amount of TFA used is crucial to the rate of displacement as well as to the subsequent formation of the undesired sulfide at the homotyrosine segment of the cyclic peptide. It was found that from about 5% to about 25% TFA in acetonitrile gave the best yield

and process aging time with a preferred TFA range of from about 7% to about 15%.

The amount of thiophenol used in this step is also critical to the yield of the final product. 3 to 5 equivalents of thiophenol provided the best yield.

The preferred conditions for the sulfide formation were determined to be 5 equivalents thiophenol in 10% TFA/acetonitrile at 0°C. These conditions resulted in a yield of 65-70% after solid phase extraction.

Step 2 involves the derivatization of the phenylsulfide containing intermediate by reacting it with phenylboronic acid, p-methoxyphenylboronic acid or methaneboronic acid in THF. 1-10 mole equivalents of the acid can be employed with 1-3 mole equivalents preferred.

Step 3 involves the reduction of Compound IIIa to the amine (Compound V) using a borane complex such as borane with tetrahydrofuran (THF), dimethylsulfide, diphenylsulfide, dibenzylsulfide, 1,4-oxathiane or BH₂Cl with dimethylsulfide or a metal boride such as ZrCl₄/NaBH₄ or TiCl₄/NaBH₄ in THF or other suitable solvent. The reduction may also be carried out using borane complexes with ammonia, dimethylamine, pyridine or piperazine. Preferred reduction agents include the borane complexes with tetrahydrofuran (THF), dimethylsulfide, diphenylsulfide, dibenzylsulfide, 1,4-oxathiane or BH₂Cl with dimethylsulfide or a metal boride such as ZrCl₄/NaBH₄ or TiCl₄/NaBH₄ in THF or other suitable solvent. Any amide unconverted by this reduction is separated using reverse phase chromatography.

Step 3 also involves the removal of the phenylboronate group during workup with aqueous acid.

Finally, Step 4 involves the displacement of the phenylthio group. The phenylsulfide is reacted in neat ethylenediamine (1:3) at ambient temperature to provide Compound Ia in 95% yield. The reaction may take place at a temperature of about 10°C to about 40°C for about 0.5 to about 6.0 hours. Preferably the reaction takes place at

room temperature for about 1.5 hours. The reaction can also be conducted using ethylenediamine dissolved in a suitable solvent such as water, methanol, ethanol, isopropanol, tetrahydrofuran, trifluoroethanol, dichloroethane or acetonitrile.

Compounds III, IIIa, V and VI are novel intermediates which are useful in the process of the invention.

The invention is described in greater detail in the following examples in which all parts, preparations, ratios and percentages are by weight unless otherwise indicated. In the example, R^I was dimethyltridecyl.

EXAMPLE 1

a) The synthesis of Compound IV from Compound II (through Compound III)

Compound II (60 g gross, 52.6 g HPLC assay, 49.4 mmol) was added to dry THF (1480 mL). The PhB(OH)₂ (14.56 g, 119 mmol) was added to the suspension. The suspension was aged at room temperature then heated to reflux. During the room temperature aging and reflux, the reaction solution becomes homogeneous. The reflux condensate was passed through 3A molecular sieves in a liquid/solid extraction apparatus so as to dry the solution to less than 25 mol% water to Compound II. The reaction mixture was cooled to ambient temperature and diluted with 490 mL dry THF. The bis(phenylboronate) solution prepared above was cooled to about -7 °C and BH₃•S(CH₃)₂ (10 M, 33.3 mL, 6.7 mol equiv.) was added. The reaction was maintained at -12 to 0 °C and aged 6.5 hrs whereupon aq. HCl (2M, 140 mL, 280 mmol) was added slowly. HPLC assay indicated a 61% yield of Compound IV.

A portion of the quenched solution was diluted with water to a 1:5.7 v/v THF/water solution. This solution was loaded onto a medium-pressure liquid chromatography column of reverse-phase C-18 adsorbent. After loading, the compound IV was eluted with solutions of 1:4 v/v acetonitrile/water and then 1:3 v/v acetonitrile water.

The rich cuts (>80 HPLC area%) were combined and diluted with water to a 1:7.3 v/v acetonitrile/water solution. This mixture was loaded to the same column described above, and the column was eluted with methanol. The rich cut fractions (> 85 HPLC area%) were combined and concentrated to give a typical recovery of 88–92% of Compound IV for the chromatography and isolation.

b) The preparation of the phenylsulfide (Compound V)

Compound IV (5.80 g assay, 0.00533 mol) was charged to 0.23 L of dry acetonitrile and cooled to -5°C at which point thiophenol (3.10 g, 0.028 mol) was added. TFA (36 g, 24.5 mL, 0.318 mol) was added over 20 minutes in order to keep the temperature of the reaction mixture below 0°C . The reaction was aged at -10°C to 0°C until HPLC analysis showed < 3 area% starting material (3.75 h). At this time, chilled water (0.56 L) was added slowly (1 h) while cooling the reaction mixture to maintain the temperature below 5°C . The assay yield of the α - and β -phenylsulfide adduct as the trifluoroacetate salt was 4.82g (71%).

This solution was loaded on the same column described in step a and the column was washed with water (0.57 L), then the adsorbed organic compounds were eluted with methanol (0.50 L). The rich cuts were concentrated by rotary evaporation and static high vacuum. This yielded 7.20 g (57 wt% pure, 5.1 wt% water) of crude phenylsulfide trifluoroacetate salt as an amorphous foamy solid. The corrected isolated step yield for the phenylsulfide was 4.10 g (61%) as a 93:7 mixture of the α - and β -aminal diastereomers.

c) Conversion of the phenylsulfide to Compound Ia

The crude phenylsulfide trifluoromethanesulfonate salt (8.4 g crude, 57 wt% pure, 0.00377 mole) was added to ethylenediamine (24 mL) while stirring at ambient temperature. The resulting solution was stirred 1.5 h to complete the displacement, then methanol (40 mL) was added followed by acetic acid (45 mL), keeping the temperature below 25°C with ice-bath cooling. A thick slurry

- 25 -

resulted. Water (160 mL) was added to dissolve the slurry, and the aqueous layer was extracted by gentle shaking with hexanes (75 mL). The hexanes layer was back-extracted with water (40 mL) and the combined aq. layer was filtered through a medium-porosity sintered glass funnel, then purified by prep HPLC using a 50 mm diameter C18 column, using 22% acetonitrile/78% 0.15% aq. acetic acid as eluent. The rich cut was lyophilized to provide 4.2 g of 85 wt% pure Compound 1-1 as the diacetate salt in 78% isolated step yield.

d) Crystallization of Compound Ia

The solid (2.3 g) was dissolved in ethanol (25 mL) and water (2.7 mL) was then added. The solution was passed through a sintered glass funnel to remove extraneous matter. To this filtrate was added acetic acid (0.14 mL) followed by the slow addition (1.75 h) of ethyl acetate (14 mL). The solution was seeded and the seed bed was aged for 1 h. The remaining ethyl acetate (32 mL) was added over 5 h and aged an additional 1 h. The crystalline solid was collected on a sintered-glass funnel and washed with a solution of ethanol/ethyl acetate/water (6 mL/9 mL/0.5 mL, respectively). The wet cake was dried with a nitrogen flow to give 1.91 g (1.75 assay g, 88% recovery) of the diacetate salt of compound Ia.

EXAMPLE 2

a) The preparation of the phenylsulfide (Compound VI)

Compound II (2.48 kg assay, 2.33 mol) was charged to 78 L of dry acetonitrile and cooled to -8°C at which point thiophenol (1.08 kg, 9.8 mol) was added. TFA (12.8 kg, 8.65 L, 112 mol) was added over 30 minutes in order to keep the temperature of the reaction mixture below 0°C . The reaction was aged at -13° to 0°C until HPLC analysis showed < 3 area% starting material (5 h). At this time, chilled water (35 L) was added slowly while cooling the reaction mixture to maintain the temperature below 5°C . The product VI precipitates during water addition. Additional water was added to adjust the mixture to 1:3

v/v acetonitrile/water. The solids were removed by filtration and washed with 1:3 v/v acetonitrile/water until the pH of the filtrate was > pH 5. The solid was dried under a nitrogen flow. The assay yield of Compound VI as the trifluoroacetate salt was 2.03 kg (76%).

b) The synthesis of Compound V from Compound VI
 (Through Compound IIIa)

Compound VI (922 g assay, 0.94 mol) was added to dry THF (44 L). The PhB(OH)_2 (119 g, 0.98 mol) was added to the suspension. The suspension was aged at room temperature for 12 hours, then heated to reflux. The reflux condensate was passed through 3A molecular sieves in a liquid/solid extraction apparatus so as to dry the solution to less than 25 mol% water to Compound VI. The reaction mixture was cooled and additional dry THF was added to reconstitute the mixture to the original volume. The mixture was cooled to $< -4^\circ\text{C}$. Neat $\text{BH}_3\cdot\text{SMe}_2$ (494 g, 6.51 mol) was added over 15 minutes and the reaction mixture was maintained at -4 to 0°C . The reaction progress was monitored by HPLC until $< 30\%$ of the starting material remained, indicating the end of the reaction age (9 hours).

The mixture was cooled to -10°C and slowly quenched with 2N HCl (2.98 L). The assay yield of Compound V as the hydrochloride salt was 573 g (61%).

The quenched solution was diluted to 1:3.76 v/v THF/water and loaded onto a medium-pressure column of RP-C18 adsorbent (16.8 kg). After loading, the column was eluted with 1:2.64 v/v acetonitrile/water, and then 1:2.45 v/v acetonitrile/water. The rich cuts (> 80 HPLC area%) were combined to give a 90% yield of Compound V.

The combined rich cuts were diluted with water to a 1:2 v/v acetonitrile/water solution. This mixture was combined with the diluted rich cuts of a similar size reduction batch and loaded to the same column described above. The desired compound V was eluted with methanol. The rich cut fractions (> 85 area%) were combined and concentrated by rotary evaporation to give a 98% recovery of Compound V.

Compound V was converted to Compound Ia as described
above in Examples 1c and 1d.

- 28 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Leonard, William
Belyk, Kevin M
- (ii) TITLE OF THE INVENTION: A Process for Preparing Certain
Aza Cyclohexapeptides
- (iii) NUMBER OF SEQUENCES: 1
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Merck & Co., Inc.
 - (B) STREET: P.O. Box 2000, 126 E. Lincoln Ave.
 - (C) CITY: Rahway
 - (D) STATE: NJ
 - (E) COUNTRY: USA
 - (F) ZIP: 07065-0900
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Korsen, Elliot
 - (B) REGISTRATION NUMBER: 32,785
 - (C) REFERENCE/DOCKET NUMBER: 19726
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 908-594-5493
 - (B) TELEFAX: 908-594-4720
 - (C) TELEX:

- 29 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: circular


(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Thr Xaa Xaa Xaa Xaa
1 5

WHAT IS CLAIMED IS:

1. A process for preparing aza cyclohexapeptide compounds of the formula



wherein

R_I is CH₂CH₂NH₂ or CH₂CONH₂;

R^I is C₉-C₂₁ alkyl,
C₉-C₂₁ alkenyl,
C₁-C₁₀ alkoxyphenyl,
C₁-C₁₀ alkoxyphenyl, or
C₁-C₁₀ alkoxyterphenyl;

R^{II} is H, C₁-C₄ alkyl,
C₃-C₄ alkenyl,
(CH₂)₂₋₄OH, or
(CH₂)₂₋₄NR^{IV}R^V;

- 31 -

R^{III} is H, C₁-C₄ alkyl C₃-C₄ alkenyl, (CH₂)₂₋₄OH,
~~(CH₂)₂₋₄NR^{IV}R^V, or~~

R^{II} and
 R^{III} taken together are (CH₂)₄, (CH₂)₅, (CH₂)₂O(CH₂)₂ or
 (CH₂)₂NH(CH₂)₂;


R^{IV} is H or C₁-C₄ alkyl;

R^V is H or C₁-C₄ alkyl;


Q is N or O; or

pharmaceutically acceptable acid addition salts thereof which comprises
 the steps of


a) reacting Compound II of the formula:




with phenylboronic acid, p-methoxyphenylboronic acid or methanaboronic acid to afford Compound III of the formula:



- b) which is subsequently reduced to the amine and hydrolyzed to afford Compound IV of the formula:



- c) which is reacted with thiophenol in a suitable solvent to afford Compound V of the formula;



which is stereoselectively converted to Compound 1 by displacement of the phenylthio group.

2 The process of Claim 1 wherein the reduction in Step (b) is accomplished using a borane complex or metal boride.

3. The process of Claim 2 wherein the metal boride is $\text{ZrCl}_4/\text{NaBH}_4$ or $\text{TiCl}_4/\text{NaBH}_4$ and the borane complex is borane complexed with dimethylsulfide, dibenzylsulfide, diphenylsulfide, THF or 1,4-oxathiane or BH_2Cl with dimethylsulfide.


4. The process of Claim 1 wherein the suitable solvent in Step (c) is acetonitrile.

- 35 -

5. The process of Claim 1 where the displacement of the phenylthio group takes place in neat ethylenediamine or with ~~ethylenediamine dissolved in a suitable solvent at a temperature of about 10°C to about 40°C.~~

6. The process of Claim 5 wherein the suitable solvent is selected from water, methanol, ethanol, tetrahydrofuran, isopropanol, trifluoroethanol, acetonitrile or dichloromethane.

7. A process for preparing aza cyclohexapeptide compounds of the formula



wherein

R₁ is CH₂CH₂NH₂ or CH₂CONH₂;

R^I is C₉-C₂₁ alkyl,
C₉-C₂₁ alkenyl,
C₁-C₁₀ alkoxyphenyl,

- 36 -

C₁-C₁₀ alkoxyphenyl, or
C₁-C₁₀ alkoxyterphenyl:

R^{II} is H, C₁-C₄ alkyl,
C₃-C₄ alkenyl,
(CH₂)₂₋₄OH, or
(CH₂)₂₋₄NR^{IV}R^V;

R^{III} is H, C₁-C₄ alkyl C₃-C₄ alkenyl, (CH₂)₂₋₄OH,
(CH₂)₂₋₄NR^{IV}R^V, or

R^{II} and
R^{III} taken together are (CH₂)₄, (CH₂)₅, (CH₂)₂O(CH₂)₂ or
(CH₂)₂NH(CH₂)₂;


R^{IV} is H or C₁-C₄ alkyl;

R^V is H or C₁-C₄ alkyl; or


pharmaceutically acceptable acid addition salts thereof which comprises
the steps of

a) reacting Compound II of the formula

- 37 -




with thiophenol to afford Compound VI of the formula:




- 38 -

- b) subsequently reacting Compound VI with phenylboronic acid, p-methoxyphenylboronic acid or methaneboronic acid to afford Compound IIIa of the formula:



- c) which is subsequently reduced to the amine and hydrolyzed to afford Compound V of the formula:



- d) which is stereoselectively converted to Compound I by the displacement of the phenylthio group.

8. The process of Claim 7 wherein the reduction in Step (c) is accomplished using a borane complex or metal boride.

9. The process of Claim 8 wherein the metal boride is $\text{ZrCl}_4/\text{NaBH}_4$ or $\text{TiCl}_4/\text{NaBH}_4$ and the borane complex is borane complexed with dimethylsulfide, dibenzylsulfide, diphenylsulfide, THF or 1,4-oxathiane or BH_2Cl with dimethylsulfide.


10. The process of Claim 7 wherein Compound II is converted to the phenylsulfide by reaction with thiophenol in a suitable solvent.

11. The process of Claim 10 wherein the suitable solvent is acetonitrile.

12. The process of Claim 7 where the displacement of the phenylthio group takes place in neat ethylenediamine or with ethylenediamine dissolved in a suitable solvent at a temperature of about 10°C to about 40°C.


13. The process of Claim 12 wherein the suitable solvent is selected from water, methanol, ethanol, tetrahydrofuran, isopropanol, trifluoroethanol, acetonitrile or dichloromethane.

14. The process of Claim 1 wherein a compound of the formula




or a pharmaceutically acceptable salt thereof is prepared.

15. The process of Claim 7 wherein a compound of the formula




or a pharmaceutically acceptable salt thereof is prepared.

16. The process of Claim 1 wherein a compound of the formula



or a pharmaceutically acceptable salt thereof is prepared.


17. A compound of the formula




wherein
R¹ is

C₉-C₂₁ alkyl,
C₉-C₂₁ alkenyl,
C₁-C₁₀ alkoxyphenyl,
C₁-C₁₀ alkoxynaphthyl, or
C₁-C₁₀ alkoxyterphenyl.

18. A compound of the formula




19. A compound of the formula



wherein
R^I is

C₉-C₂₁ alkyl,
C₉-C₂₁ alkenyl,
C₁-C₁₀ alkoxyphenyl,
C₁-C₁₀ alkoxynaphthyl, or
C₁-C₁₀ alkoxyterphenyl.

20. A compound of the formula



wherein
 R^I is

C9-C21 alkyl,
C9-C21 alkenyl,
C1-C10 alkoxyphenyl,
C1-C10 alkoxyphenyl, or
C1-C10 alkoxyterphenyl.

INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/US 97/09833

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K7/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 21677 A (MERCK & CO INC ;BALKOVEC JAMES M (US); BOUFFARD FRANCES AILEEN (US) 29 September 1994 see the whole document ---	1-20
P,X	US 5 552 521 A (BELYK KEVIN M ET AL) 3 September 1996 cited in the application see claims 1,4,8 -----	18,20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

15 October 1997

Date of mailing of the international search report

29. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

information on patent family members

Intern 1st Application No

PCT/US 97/09833

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9421677 A	29-09-94	US 5378804 A	03-01-95
		AU 668804 B	16-05-96
		AU 5783294 A	22-09-94
		BG 99999 A	30-04-96
		BR 9406009 A	26-12-95
		CA 2118757 A	17-09-94
		CN 1119441 A	27-03-96
		CZ 9502358 A	14-02-96
		EP 0620232 A	19-10-94
		FI 954327 A	14-09-95
		HR 940161 A	31-08-96
		HU 9500565 A	30-10-95
		HU 73496 A	28-08-96
		JP 2568474 B	08-01-97
		JP 6321986 A	22-11-94
		NO 953648 A	15-11-95
		PL 310634 A	27-12-95
		SI 9420013 A	31-08-96
		SK 113695 A	07-02-96
		US 5514650 A	07-05-96
		ZA 9401807 A	13-10-94

US 5552521 A	03-09-96	NONE	
